Antineoplastic Agents, Alkylating

"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Descriptor ID	D018906
MeSH Number(s)	D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
Concept/Terms	Antineoplastic Agents, Alkylating Antineoplastic Agents, Alkylating Alkylating Antineoplastic Agents Alkylating Antineoplastic Drugs Alkylating Antineoplastics Antineoplastic Alkylating Agents Antineoplastic Drugs, Alkylating Antineoplastics, Alkylating Alkylating Agents, Antineoplastic Alkylating Drugs, Antineoplastic Antineoplastic Alkylating Drugs Drugs, Antineoplastic Alkylating

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Alkylating Agents [D27.505.519.124]
Antineoplastic Agents, Alkylating [D27.505.519.124.035]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Alkylating [D27.505.954.248.150]
Toxic Actions [D27.888]
Noxae [D27.888.569]
Alkylating Agents [D27.888.569.035]
Antineoplastic Agents, Alkylating [D27.888.569.035.035]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Alkylating".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.

Bar chart showing 39 publications over 19 distinct years, with a maximum of 5 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1997	0	3	3
1998	2	0	2
2000	2	0	2
2004	2	0	2
2005	1	1	2
2007	2	0	2
2008	0	1	1
2009	3	0	3
2010	0	2	2
2011	1	1	2
2012	3	0	3
2014	1	1	2
2015	0	1	1
2016	3	2	5
2018	0	1	1
2020	1	1	2
2021	1	1	2
2022	0	1	1

Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.

Perlow HK, Yaney A, Yang M, Klamer B, Matsui J, Raval RR, Blakaj DM, Arnett A, Beyer S, Elder JB, Ammirati M, Lonser R, Hardesty D, Ong S, Giglio P, Pillainayagam C, Goranovich J, Grecula J, Chakravarti A, Gondi V, Brown PD, Palmer JD. Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol. 2022 Jan; 156(2):399-406.

View in: PubMed
Manea AJ, Ray SK. Regulation of autophagy as a therapeutic option in glioblastoma. Apoptosis. 2021 12; 26(11-12):574-599.

View in: PubMed
do Reis SRR, Helal-Neto E, da Silva de Barros AO, Pinto SR, Portilho FL, de Oliveira Siqueira LB, Alencar LMR, Dahoumane SA, Alexis F, Ricci-Junior E, Santos-Oliveira R. Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma. Pharm Res. 2021 Feb; 38(2):335-346.

View in: PubMed
Das A, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.

View in: PubMed
Das A, Henderson FC, Alshareef M, Porto GBF, Kanginakudru I, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. MGMT-inhibitor in combination with TGF-ßRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.

View in: PubMed
Grek CL, Sheng Z, Naus CC, Sin WC, Gourdie RG, Ghatnekar GG. Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol. 2018 08; 41:79-88.

View in: PubMed
Shields CL, Alset AE, Say EA, Caywood E, Jabbour P, Shields JA. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016 Sep 01; 53(5):275-84.

View in: PubMed
Kamiya-Matsuoka C, Cachia D, Waguespack SG, Crane CH, Mahajan A, Brown PD, Nam JY, McCutcheon IE, Penas-Prado M. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary. 2016 Aug; 19(4):415-21.

View in: PubMed
Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis. JAMA Neurol. 2016 07 01; 73(7):821-8.

View in: PubMed
Miller K, Dixit S, Bredlau AL, Moore A, McKinnon E, Broome AM. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond). 2016 Mar; 11(6):581-95.

View in: PubMed

People

Explore

Similar Concepts

Top Journals